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Abstract 
Purpose: To investigate the safety and potential pharmacokinetic (PK) interaction between retagliptin, a 
selective inhibitor of dipeptidyl peptidase-4, and metformin in healthy subjects. 
Methods: In open-label, randomized, three-period, three-treatment crossover studies, 15 subjects 
received 100 mg retagliptin, 1500 mg metformin or the combination. The area under the curve from the 
time of dosing to infinity (AUCinf) and the maximum observed plasma concentration (Cmax) of each drug 
were measured.  
Results: The combination of retagliptin and metformin did not result in clinically significant alterations in 
the pharmacokinetics of SP2086 or metformin. The AUCinf and Cmax of retagliptin co-administered with 
metformin were 16.49 and 25.88 % higher than for retagliptin alone, respectively, while the AUCinf of 
metformin co-administered with retagliptin was 22.06 % higher than for metformin alone. The 90 % 
confidence interval of both glucose-lowering drugs’ AUCinf and Cmax of the geometric mean ratios of 
SP2086 + metformin fell within the pre-specified interval of 80 - 125 %. No laboratory adverse 
conditions occurred during the study. Retagliptin appeared generally safe and well-tolerated when 
administered alone or in combination with metformin. 
Conclusion: The results may be an indication that no dose adjustments are likely to be required when 
retagliptin is given in combination with metformin. 
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Diabetes is a serious public health problem [1-3]. 
Yang et al has shown that in China, age-
standardized prevalence of total diabetes (which 
include both previously diagnosed diabetes and 
previously undiagnosed diabetes) and 
prediabetes was 9.7 % (10.6 % among men and 
8.8 % among women) and 15.5 % (16.1 % 
among men and 14.9 % among women), 
respectively, accounting for 92.4 million adults 
with diabetes (50.2 million men and 42.2 million 
women) and 148.2 million adults with 
prediabetes (76.1 million men and 72.1 million 
women) [4].  
 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a 
relatively new class of drugs for the management 
of type 2 diabetes [5]. Inhibitors stimulate insulin 
secretion in a glucose-dependent manner, DPP-
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4 inhibitors present lower risks on hypoglycemia 
and may not lead to weight gain, also protect 
pancreatic beta cells. The up-regulation of gastric 
inhibitory polypeptide and pituitary adenylate 
cyclase activating polypeptide by DPP-4 inhibitor 
also result in blood glucose reduction [6,7]. 
Clinical data indicate that treatment with DPP-4 
inhibitors, in combination with other 
hypoglycemic drugs result in significantly 
improved glycemic control compared with DPP-4 
inhibitor or metformin alone in patients with type 
2 diabetes mellitus (T2DM) [8,9].  
 
Retagliptin is a novel DPP-4 inhibitor. Its 
chemical structure was shown in the Figure 1. 
Retagliptin has entered into clinical trial phase II 
in USA under approval by FDA. Our previous 
clinical studies of retagliptin in healthy volunteers 
showed a dose-dependent manner in DPP-4 
inhibition present a good correlation between 
DPP-4 inhibition ratio and plasma concentration 
of retagliptin acid. The objective of the present 
study was to establish a method to evaluate the 
safety and pharmacokinetic interaction of 
synergism of retagliptin combined with metformin 
in healthy subjects, and to support a clinical 










The experiment was designed for single center, 
randomized, opened and three period crossover. 
The study was carried out in the national clinical 
drug trial institution of the General Hospital of 
Chengdu Military Region. The study was 
approved and registered by the hospital’s Ethics 
Committee in July in 2011 (approval no. CDJ-11-
07-03). All subjects signed written informed 
consent form and all aspects of the work were 
undertaken according to the provisions of the 
Declaration of Helsinki. 
 
Main inclusion criteria include that participants 
should be healthy male and female; female 
should not be pregnant using acceptable method 
contraception; and subjects aged 18 - 45 years, 
with a body mass index of 19 - 24 were eligible 
for inclusion. Routine inspection of their medical 
history, vital signs, safety laboratory tests and 
electrocardiograms (ECGs) were conducted to 
determine eligibility for the studies. 
 
The main exclusion criteria include history of 
allergies or hypersensitivity to the study drugs or 
their excipients; abuse of drugs or alcohol within 
6 months prior to enrollment; use of prescription 
medications or herbal preparations within 4 
weeks prior to enrollment; and use of over-the-
counter medication or vitamins within 2 weeks 
prior to enrollment. Volunteers with evidence of 
organ dysfunction or any clinically significant 
deviations from normal in physical examinations, 
vital signs, electrocardiogram (ECG), or clinical 
laboratory determinations which may affect drug 





The study was an open-label, randomized, 3-
period, 3-treatment (A, B, C), crossover study in 
healthy subjects. The dosage of retagliptin used 
in this study was determined by previous trials of 
single and multiple-dose administration of 
retagliptin alone. a total of 15 eligible subjects 
were randomized to 1 of 3 possible treatment 
sequences (ABC, BCA, CAB) and to receive the 
following 3 treatment: treatment A, retagliptin 
(100 mg q.d.); treatment B, metformin (1500 mg 
q.d.); treatment C, retagliptin (100 mg q.d.) + 
metformin (1500 mg q.d.). A 5-day washout 
period was employed between 5-day treatments 
periods, after which subjects were crossed over 
to receive the next treatment specified in their 
treatment sequence. Blood samples were 
collected at 2, 3, 4, 5 day following 
administration. To confirm steady-state 
concentration following co-administration, blood 
samples prior to administration on 2nd, 3rd and 
4th day were analyzed. Figure 2 shows the study 
design. 
 
Subjects were admitted to a clinical unit one day 
prior to each study phase with fasting overnight 
for at least 8 h. Then they received medicine with 
plain water (retagliptin 100mg or metformin 1500 
mg or retagliptin 100 mg + metfromin 1500 mg) 
after taking baseline examination in the next 
morning. Subjects were administered medicine 
before meal every day. Standard meals were 
served during each treatment periods. Drugs 
were administered after a 4 - h fast and subjects 
should leave clinical unit until all the plasma 
sample collection were finished in the 5 days of 
each treatment phase. 
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Safety assessment was based on the 
characteristics, frequency and severity of 
adverse events; signs and symptoms of 
hypoglycemia; physical examination and vital 
signs; routine safety laboratory tests; urinalysis; 
hematology; biochemistry and a 12-lead ECG. 
 
The subjects underwent safety examinations 
before the first dosing, 4 h after fifth dosing in 
each phase, and after the last blood collection 
respectively. If abnormal signs were detected in 
the third phase before the end of the trials, 
following up visit is necessary until the patients 
return to normal condition. During the whole 
clinical trials the subjects should keep bland diet, 
avoid strenuous exercises and long period of bed 
rest. They were forbiddance of juice, tea, and 
coffee, alcohol which contains caffeine or 
alcohol. Cigarettes or anything that can affect the 
pharmacokinetics or safety evaluation were 
forbidden. 
 
Pharmacokinetic analysis and bioanalysis 
 
Blood samples for determination of drug 
concentration and pharmacokinetics were 
collected at specific time points, depending on 
the characteristics of each drug. 
 
Plasma concentrations of retagliptin, retagliptin 
acid (a main metabolite of retagliptin), metformin 
were determined by separated, validated liquid 
chromatography-tandem mass spectrometry 
methods [10,11]. The linearity ranges of 
quantitative detection were 2-200 ng/mL for 
retagliptin; 5 - 1000 ng/mL for retagliptin acid; 50 
- 2000 ng/mL for metformin. The lower limit of 
quantitation was 2 ng/mL for retagliptin, 5 ng/mL 
for retagliptin acid and 50 ng/mL for metformin. 
The difference between variability for the quality 
controls of retagliptin was < 8.4 and < 7.8 %, 
respectively. The difference between variability 
for the quality controls of retagliptin acid was < 
10.8 and < 9.8 %, respectively. The difference 
between variability for the quality controls of 




Descriptive statistics including mean, standard 
deviation, relative standard deviation (RSD), 
minimum and maximum (range), median and % 
CV for continuous variables; and also number, 
frequency and percentage were conducted. 
Pharmacokinetic parameters were calculated by 
non-compartmental methods using WinNonlin 
software version 6.1 (Pharsight Corp, Mountain 
View, CA, USA) for plasma. 
 
Pharmacokinetics interactions were assessed by 
bioequivalency assay. Absence of statistically 
significant interaction between retagliptin and 
metformin was confirmed if the 90 % confidence 
interval (CI) of both glucose-lowering drugs’ 
AUCinf and Cmax of the geometric mean ratios 
(GMRs) of retagliptin + metformin versus 
retagliptin alone, fell within the pre-specified 






Table 1 showed the descriptive statistics of the 
pharmacokinetic parameters for retagliptin with 
or without metformin. Table 2 shows the GMRs 
and 90 % CI of AUCinf and Cmax for retagliptin 
with or without metformin. 
 
As can be seen from Tables 1 and 2, when 
retagliptin was co-administered with metformin, 
the AUCinf and Cmax of retagliptin were 16.49 and 
25.88 % higher than retagliptin alone 
respectively, and the GMRs and 90 % CI for the 
ratios of AUCinf and Cmax were beyond the upper 
limit of the interval (80 - 125 %). 
 
Yong et al 
Trop J Pharm Res, August 2015; 14(8): 1484  
 
When retagliptin was co-administered with 
metformin, the Cmax of retagliptin acid increased, 
and the GMRs and 90 % CI for the ratios of 
AUCinf and Cmax fell within the predefined interval 
(80 - 125 %). 
 
When retagliptin was co-administered with 
metformin, the AUCinf of metformin increased 
21.77 %, and the GMRs and 90 % CI for the 
ratios of AUCinf and Cmax fell within the 
predefined interval (80 % - 125 %). The time 
profile of the drugs in plasma concentration is 
displayed in Figure 3. 
 
Safety and tolerability 
 
During the clinical trials, all subjects were well 
monitored by researchers.  
 
There were no serious adverse events in the 
whole trials. The adverse events mainly were 
gastro-intestinal tract response including nausea, 
anorexia, sickness and diarrhea. Central nervous 
system symptoms including dizziness and 
sleepiness appeared in few subjects. The AE 
incidence rate of metformin treatment alone was 
much higher than retagliptin treatment alone. The 
AE incidence rate and type of combination 
treatment was similar with retagliptin or 
metformin alone. One female subject from the 
metformin alone group took place moderate 
diarrhea. The symptoms continued 5 days until 
the drug withdrawal. The rest of the adverse 
events were all mild situations. The subjects 
alleviate by themselves without treatment. All 
treatments in the trials were well tolerated. The 
most frequently reported AEs were summarized 
in Table 3. 
 
No laboratory adverse conditions, including 
hypoglycemia, or treatment-related clinically 
significant deviations in physical examinations 
and ECG parameters occurred during the study. 
 
 
Table 1: Pharmacokinetic parameters for retagliptin with or without metformin 
 
Drug Parameter Unit  Retagliptin Retagliptin+ metformin Mean SD RSD (%) Mean SD RSD(%) 
Retagliptin 
t1/2z h 8.3 2.3 28.0 7.8 1.4 19.0 
T max h 1.0 0.5 50.0 1.0 0.7 70.5 
C max µg/ml 64.9 35.0 54.0 81.7 40.0 48.9 
AUC las h*µg/ml 295.47 68.1 23.0 344.2 73.0 21.2 
AUC inf h*µg/ml 336.84 72.0 21.4 386.55 72.9 18.8 
Retagliptin 
acid 
t1/2z h 6.1 1.9 32.0 6.1 1.6 26.8 
T max h 1.3 0.4 36.6 1.4 0.5 39.2 
C max µg/ml 1002.98 397.31 39.6 1091.30 379.57 34.7 
AUC las h*µg/ml 3263.50 623.22 19.1 3469.05 726.15 20.9 
AUC inf h*µg/ml 3374.98 630.62 18.6 3583.96 739.66 20.6 
Metformin 
t1/2z h 6.8 3.5 50.9 6.7 2.4 36.6 
T max h 3.3 0.8 26.7 4.0 1.1 28.6 
C max µg/ml 1318.11 282.10 21.4 1226.16 358.95 29.2 
AUC las h*µg/ml 9591.99 2315.55 24.1 11680.45 3993.10 34.1 
AUC inf h*µg/ml 10477.14 2266.71 21.6 12788.83 4464.85 34.9 
 
Table 2: GMRs and 90 % CI of AUCinf and Cmax for retagliptin with or without metformin 
 
Drug Parameter Combination/alone 90 % confidence Interval 
Retagliptin C max 122.5 90.59 % - 165.69 % AUC las 119.0 110.71 % - 128.06 % 
Retagliptin acid C max 112.7 91.89 % - 138.27 % AUC las 107.9 102.98 % - 113.19 % 
Metformin C max 92.4 77.51 % - 110.34 % AUC las 119.9 98.049 % - 146.65 % 
 
Table 3: Most common adverse events 
 
Event/reaction Medicine group Positive Negative Total Incidence rate (%) P-value 
Adverse  
event 
A 3 12 15 20.00 
0. 0026 B 10 5 15 66.67 
C 12 3 15 80.00 
Adverse reaction 
A 2 13 15 13.33 
0. 0007 B 10 5 15 66.67 
C 12 3 15 80.00 
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Fig 3: Drug concentration-time of retagliptin, retagliptin 




Retagliptin has similar chemical structure with 
vildagliptin (retagliptin), a new DPP-4 inhibitor 
[12,13]. Our pre-clinical studies have 
demonstrated that retagliptin has similar 
mechanism to vildagliptin when compared with 
sitagliptin [14,15]. Retagliptin has more effective 
than sitagliptin in vitro inhibition activity in several 
diabetes animal models. This will need to be 
further proved eventually in human patients with 
diabetes mellitus.  
 
In an attempt to clarify the safety and potential 
pharmacokinetic interaction between retagliptin, 
a selective inhibitor of DPP-4, and metformin, we 
studied their PK interaction in healthy subjects. 
With this approach it was possible to prove that 
the combination increased the system exposure 
of both metformin and retagliptin. Compared with 
using retagliptin alone, the Cmax increased by 
25.88 % in retagliptin combined with metformin 
hydrochloride sustained-release tablets; the AUC 
increased by 16.49 %. The 90 % confidence 
interval of AUC ratio of retagliptin acid 
combination with metformin/retagliptin acid alone 
was 80 - 125 %, the combination use of drug 
increased Cmax slightly compared with using drug 
alone, So dose adjustment is needed when 
retagliptin combining used with metformin in 
actual situation, and should be adjusted 
according to related clinical curative effect 
analysis and judgment. 
 
Our results showed that the combination 
increased the system exposure of both 
metformin and retagliptin, which may be related 
to the kidney excretion style of the both drugs. It 
was reported that metformin itself was able to 




The combination of retagliptin and metformin 
leads not only to significantly higher Cmax and 
AUCinf of retagliptin but also higher AUCinf of 
metformin. However, there is no pharmacokinetic 
interaction between metformin and sitagliptin 
[17]. The dosage of metformin between 1000 mg 
and 2500 mg produces similar incidence of 
gastrointestinal side effects with no obvious dose 
- effect relationship. No dose-adjustments are 
likely to be required when retagliptin is given in 
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